Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merrimack Pharmaceuticals
Phase 1: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to evaluate the safety, tolerability and recommended Phase 2 dose of MM-121 in combination with standard therapy.
Phase 2: Patients with Non-Small Cell Lung Cancer (NSCLC) may be enrolled to estimate the progression-free survival of the MM-121 + standard therapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with locally advanced or metastatic non-small cell lung cancer.
Patients must be \>/= 18 years of age.
Patients must have adequate Performance Status (PS) as measured by ECOG and adequate end organ function.
You may not be if
Patients with a recent history (within 5 years) of another malignancy.
Patients who are pregnant or nursing.
Patients with clinically significant heart failure.
Patients with clinically significant eye or gastrointestinal abnormalities.
Clareo Health | A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
